Skin-on-a-chip model simulating inflammation, edema and drug-based treatment

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wufuer, Maierdanjiang ^a   Lee, GeonHui ^b   Hur, Woojune ^a   Jeon, Byoungjun ^a   Kim, Byung Jun ^a   Choi, Tae Hyun ^a   Lee, SangHoon ^b  

^a Seoul National University   (South Korea)

^b Korea University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; PROTECTIVE AGENT; TUMOR NECROSIS FACTOR;

BIOLOGICAL MODEL; DRUG EFFECT; EDEMA; FLUORESCENCE IMAGING; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LAB ON A CHIP; METABOLISM; PATHOLOGY; SKIN; TIGHT JUNCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

DEXAMETHASONE; EDEMA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LAB-ON-A-CHIP DEVICES; MODELS, BIOLOGICAL; OPTICAL IMAGING; PROTECTIVE AGENTS; SKIN; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84995968685     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep37471     Document Type: Article

References (54)

1. Taylor, K., Gordon, N., Langley, G. & Higgins, W. Estimates for worldwide laboratory animal use in 2005. ATLA-Alternatives to Laboratory Animals 36, 327 (2008).
2. Serpell, J. In the company of animals: A study of human-animal relationships. (Cambridge University Press, 1996).
3. Schmook, F. P., Meingassner, J. G. & Billich, A. Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption. Int. J. Pharm. 215, 51-56 (2001).
4. Pound, P. & Bracken, M. B. Is animal research sufficiently evidence based to be a cornerstone of biomedical research. BMJ 348, g3387 (2014).
5. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature reviews Drug discovery 3, 711-716 (2004).
6. Bell, E., Ehrlich, H. P., Buttle, D. J. & Nakatsuji, T. Living tissue formed in vitro and accepted as skin-equivalent tissue of full thickness. Science 211, 1052-1054 (1981).
7. Netzlaff, F., Lehr, C.-M., Wertz, P. & Schaefer, U. The human epidermis models EpiSkinR, SkinEthicR and EpiDermR: an evaluation of morphology and their suitability for testing phototoxicity, irritancy, corrosivity, and substance transport. Eur. J. Pharm. Biopharm. 60, 167-178 (2005).
8. Sato, Y. & Ohshima, T. The expression of mRNA of proinflammatory cytokines during skin wound healing in mice: a preliminary study for forensic wound age estimation (II). Int. J. Legal Med. 113, 140-145 (2000).
9. Waykole, Y. P., Doiphode, S., Rakhewar, P. & Mhaske, M. Anticytokine therapy for periodontal diseases: where are we now? J. Indian Soc. Periodontol. 13, 64 (2009).
10. Grossman, R. M. et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl. Acad. Sci. USA 86, 6367-6371 (1989).
11. Gomi, T., Shiohara, T., Munakata, T., Imanishi, K. i. & Nagashima, M. Interleukin 1 {alpha}, Tumor Necrosis Factor {alpha}, and Interferon {gamma} in Psoriasis. Arch. Dermatol. 127, 827 (1991).
12. Olaniran, A. K. et al. Cytokine expression in psoriatic skin lesions during PUVA therapy. Arch. Dermatol. Res. 288, 421-425 (1996).
13. Arai, K.-i. et al. Cytokines: coordinators of immune and inflammatory responses. Annu. Rev. Biochem. 59, 783-836 (1990).
14. Lowry, S. F. Cytokine mediators of immunity and inflammation. Arch. Surg. 128, 1235-1241 (1993).
15. Heinrich, P. C., Castell, J. V. & Andus, T. Interleukin-6 and the acute phase response. Biochem. J. 265, 621 (1990).
16. Van Zee, K. J. et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc. Natl. Acad. Sci. USA 89, 4845-4849 (1992).
17. Grellner, W. Time-dependent immunohistochemical detection of proinflammatory cytokines (IL-1β, IL-6, TNF-α) in human skin wounds. Forensic Sci. Int. 130, 90-96 (2002).
18. Dumont, C., Prieto, P., Asturiol, D. & Worth, A. Review of the availability of in vitro and in silico methods for assessing dermal bioavailability. Applied In Vitro Toxicology 1, 147-164 (2015).
19. Abaci, H. E., Gledhill, K., Guo, Z., Christiano, A. M. & Shuler, M. L. Pumpless microfluidic platform for drug testing on human skin equivalents. Lab Chip 15, 882-888 (2015).
20. Groeber, F., Holeiter, M., Hampel, M., Hinderer, S. & Schenke-Layland, K. Skin tissue engineering - in vivo and in vitro applications. Adv. Drug Deliv. Rev. 63, 352-366 (2011).
21. Reijnders, C. M. et al. Development of a full-thickness human skin equivalent in vitro model derived from TERT-immortalized keratinocytes and fibroblasts. Tissue Eng. Part A 21, 2448-2459 (2015).
22. Mathes, S. H., Ruffner, H. & Graf-Hausner, U. The use of skin models in drug development. Adv. Drug Deliv. Rev. 69, 81-102 (2014).
23. Chau, D. Y., Johnson, C., MacNeil, S., Haycock, J. W. & Ghaemmaghami, A. M. The development of a 3D immunocompetent model of human skin. Biofabrication 5, 035011 (2013).
24. Asbill, C. et al. Evaluation of a human bio-engineered skin equivalent for drug permeation studies. Pharm. Res. 17, 1092-1097 (2000).
25. Alepee, N., Robert, C., Tornier, C. & Cotovio, J. The usefulness of the validated SkinEthic™ RHE test method to identify skin corrosive UN GHS subcategories. Toxicol. In Vitro 28, 616-625 (2014).
26. Michael, S. et al. Tissue engineered skin substitutes created by laser-assisted bioprinting form skin-like structures in the dorsal skin fold chamber in mice. PloS one 8, e57741 (2013).
27. Atac, B. et al. Skin and hair on-a-chip: in vitro skin models versus ex vivo tissue maintenance with dynamic perfusion. Lab Chip 13, 3555-3561 (2013).
28. Ramadan, Q. & CHIA, W. T. In vitro micro-physiological immune-competent model of the human skin. Lab Chip (2016).
29. Ramadan, Q. & Ting, F. C. W. In vitro micro-physiological immune-competent model of the human skin. Lab Chip 16, 1899-1908 (2016).
30. Tracy, L. E., Minasian, R. A. & Caterson, E. J. Extracellular Matrix and Dermal Fibroblast Function in the Healing Wound. Adv Wound Care (New Rochelle). 1;5(3), 119-136 (2016).
31. Collins, T. Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Lab. Invest. 68, 499-508 (1993).
32. Aran, K., Sasso, L. A., Kamdar, N. & Zahn, J. D. Irreversible, direct bonding of nanoporous polymer membranes to PDMS or glass microdevices. Lab Chip 10, 548-552 (2010).
33. Lee, K. S. & Ram, R. J. Plastic-PDMS bonding for high pressure hydrolytically stable active microfluidics. Lab Chip 9, 1618-1624 (2009).
34. Pober, J. S. & Cotran, R. S. Cytokines and endothelial cell biology. Physiol. Rev. 70, 427-451 (1990).
35. Castro-Caldas, M., Mendes, A., Carvalho, A., Duarte, C. & Lopes, M. Dexamethasone prevents interleukin-1β-induced nuclear factor-κ B activation by upregulating Iκ B-α synthesis, in lymphoblastic cells. Mediators Inflamm. 12, 37-46 (2003).
36. Maaser, C. et al. Colonic epithelial cells induce endothelial cell expression of ICAM-1 and VCAM-1 by a NF-κ B-dependent mechanism. Clin. Exp. Immunol. 124, 208-213 (2001).
37. Kułdo, J. M. et al. Differential effects of NF-κ B and p38 MAPK inhibitors and combinations thereof on TNF-α-and IL-1β-induced proinflammatory status of endothelial cells in vitro. Am. J. Physiol. Cell Physiol. 289, C1229-C1239 (2005).
38. Karin, M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene. 22;18(49), 6867-6874 (1999).
39. Grone, A. Keratinocytes and cytokines. Vet. Immunol. Immunopathol. 88, 1-12 (2002).
40. Bonifati, C. et al. Interleukin-1-beta, interleukin-6, and interferon-gamma in suction blister fluids of involved and uninolved skin and in sera of psoriatic patients. Acta Derm. Venereol. Suppl. (Stockh) 186, 23-24 (1993).
41. Uings, I. et al. Effects of dexamethasone on TNF-alpha-induced release of cytokines from purified human blood eosinophils. Clin. Mol. Allergy 3, 1 (2005).
42. Messmer, U. K., Pereda-Fernandez, C., Manderscheid, M. & Pfeilschifter, J. Dexamethasone inhibits TNF-α -induced apoptosis and IAP protein downregulation in MCF-7 cells. Br. J. Pharmacol. 133, 467-476 (2001).
43. Liu, Q., Wang, Y. & Thorlacius, H. Dexamethasone inhibits tumor necrosis factor-α-induced expression of macrophage inflammatory protein-2 and adhesion of neutrophils to endothelial cells. Biochem. Biophys. Res. Commun. 271, 364-367 (2000).
44. Joyce, D. A., Kloda, A. & Steer, J. U. Dexamethasone suppresses release of soluble TNF receptors by human monocytes concurrently with TNF-α suppression. Immunol. Cell Biol. 75 (1997).
45. Machuca, C. et al. Dexamethasone protection from TNF-alpha-induced cell death in MCF-7 cells requires NF-kappaB and is independent from AKT. BMC Cell Biol. 7, 9 (2006).
46. Mizuno, K., Morizane, S., Takiguchi, T. & Iwatsuki, K. Dexamethasone but not tacrolimus suppresses TNF-a-induced thymic stromal lymphopoietin expression in lesional keratinocytes of atopic dermatitis model (2015).
47. Zhang, M. et al. Caffeic acid reduces cutaneous tumor necrosis factor alpha (TNF-α), IL-6 and IL-1β levels and ameliorates skin edema in acute and chronic model of cutaneous inflammation in mice. Biol. Pharm. Bull. 37, 347-354 (2014).
48. Welss, T., Basketter, D. A. & Schroder, K. R. In vitro skin irritation: facts and future. State of the art review of mechanisms and models. Toxicol. In Vitro 18, 231-243 (2004).
49. Spielmann, H. et al. The ECVAM international validation study on in vitro tests for acute skin irritation: report on the validity of the EPISKIN and EpiDerm assays and on the Skin Integrity Function Test. ATLA-Alternatives to Laboratory Animals 35, 559 (2007).
50. Hoffmann, S. Skin irritation validation study phase ii: analysis of the primary endpoint MTT and the secondary endpoint IL1-α. (IHCP-Institute of Health and Consumer Protection).
51. McKenzie, J. A. & Ridley, A. J. Roles of Rho/ROCK and MLCK in TNF-α -induced changes in endothelial morphology and permeability. J. Cell Physiol. 213, 221-228 (2007).
52. Dejana, E. Endothelial cell-cell junctions: happy together. Nat. Rev. Mol. Cell Biol. 5, 261-270 (2004).
53. Qin, D., Xia, Y. & Whitesides, G. M. Soft lithography for micro-and nanoscale patterning. Nat. Protoc. 5, 491-502 (2010).
54. Nicol, N. H. Anatomy and physiology of the skin. Dermatol. Nurs. 17, 62-63 (2005).